Mounjaro Side Effects: Incidence Rates Across Clinical Trials

What the SURPASS Trials Actually Showed About Adverse Event Rates

The SURPASS phase 3 program enrolled more than 6,000 adults with type 2 diabetes across six randomized controlled trials. Gastrointestinal adverse events were the most frequent reason for discontinuation. Nausea, diarrhea, and vomiting followed a consistent dose-response gradient: the 15 mg arm consistently showed higher rates than the 5 mg arm across every trial in the program. [1]

SURPASS-1: Monotherapy Baseline

SURPASS-1 (N=478) compared tirzepatide 5, 10, and 15 mg against placebo over 40 weeks. Nausea occurred in 12%, 14%, and 18% of the 5, 10, and 15 mg groups respectively, versus 6% on placebo. Diarrhea rates were 12%, 14%, and 17% versus 10% on placebo. Vomiting affected 5%, 6%, and 8% of tirzepatide participants versus 2% on placebo. [1]

Discontinuation due to adverse events ran at 4.1%, 5.3%, and 7.4% across the three dose groups, a figure that matters for real-world persistence modeling.

SURPASS-2: Head-to-Head With Semaglutide 1 mg

SURPASS-2 (N=1,879) is arguably the most clinically instructive trial because it placed tirzepatide directly alongside semaglutide 1 mg. Nausea was reported by 17%, 19%, and 22% of participants on tirzepatide 5, 10, and 15 mg, compared with 18% on semaglutide 1 mg, the 5 mg tirzepatide arm produced statistically similar nausea to the GLP-1 comparator. [2]

Diarrhea affected 13 to 16% of tirzepatide participants versus 12% on semaglutide. Constipation ran at 6 to 11% versus 3%. Vomiting was 6 to 10% versus 8%.

Serious adverse events occurred in 5.0%, 5.8%, and 6.3% of the tirzepatide arms versus 5.8% on semaglutide, showing no statistically significant difference in serious event burden at the trial level. [2]

SURPASS-3 Through SURPASS-5: Consistency Across Comparators

SURPASS-3 (N=1,444, vs. Insulin degludec), SURPASS-4 (N=2,002, vs. Insulin glargine), and SURPASS-5 (N=475, add-on to insulin glargine) replicated the GI profile with modest variation. Nausea rates across all three trials ranged from 10% to 20% depending on dose, and diarrhea ranged from 11% to 18%. [3][4][5]

Hypoglycemia below 54 mg/dL occurred in fewer than 1% of participants not receiving background insulin. In SURPASS-4, where all participants were on background insulin, clinically significant hypoglycemia affected 10.9% of the tirzepatide 15 mg group, compared with 21.9% on insulin glargine, reflecting the glucose-dependent mechanism of tirzepatide. [4]

GI Adverse Events: Timing, Severity, and Dose Escalation

Understanding when GI events peak helps both clinicians and patients manage expectations. The standard U.S. Prescribing information for tirzepatide specifies a dose escalation schedule starting at 2.5 mg weekly for four weeks before advancing to 5 mg, with further 2.5 mg increments every four weeks as tolerated. [6]

When Nausea Peaks

Nausea spikes within the first two to four weeks after each dose increase and typically subsides substantially within four to eight weeks at any stable dose. Data from SURMOUNT-1 (N=2,539) showed that nausea was most frequent during the first eight weeks of treatment across all tirzepatide arms, consistent with GLP-1 receptor agonist class effects on gastric emptying. [7]

Dose-Response Gradient in Detail

Across the SURPASS program, the incidence ratio between 15 mg and 5 mg doses was approximately 1.5:1 for nausea and 1.4:1 for diarrhea. That gradient is clinically meaningful: for patients who tolerate 5 mg without significant GI burden, the probability of new-onset nausea upon escalating to 10 mg is lower than the absolute trial rates suggest, because baseline-tolerant patients are a self-selected group by week 8.

Antiemetic and Dietary Strategies

The FDA prescribing label recommends taking tirzepatide with or without food and does not specify meal timing as a primary mitigation. [6] Clinical practice guidelines from the American Diabetes Association's Standards of Care in Diabetes 2024 note that dose escalation flexibility, defined as pausing an increase for four or more additional weeks, reduces GI-driven discontinuation in practice, though head-to-head data on that specific strategy remain limited. [8]

Serious and Rare Adverse Events

Serious adverse events affect a small minority of tirzepatide users, but those events carry significant clinical weight and require informed consent before prescribing.

Pancreatitis

Acute pancreatitis occurred in <0.1% of SURPASS participants across the pooled program. The FDA label carries a warning to discontinue tirzepatide if pancreatitis is confirmed. [6] Post-market surveillance through the FDA Adverse Event Reporting System (FAERS) has identified pancreatitis cases, though establishing causality in the real-world population, where many patients carry independent pancreatitis risk factors, requires careful adjudication. [9]

Gastroparesis and Gastric Stasis

Severe gastroparesis and gastric stasis emerged as post-market safety signals for the GLP-1/GIP receptor agonist class. The FDA issued a safety communication in 2023 noting cases of ileus associated with GLP-1 receptor agonists, requesting updated labeling. [10] The absolute frequency in tirzepatide-specific FAERS data remains low, but the clinical severity, including reported cases requiring hospitalization and nasogastric decompression, warrants pre-prescribing counseling, especially for patients with pre-existing motility disorders.

Thyroid C-Cell Tumors

The boxed warning in the tirzepatide label is based on rodent carcinogenicity studies showing dose-dependent thyroid C-cell tumor formation with GLP-1 receptor agonists. Human relevance is currently unknown. The label states: "It is unknown whether MOUNJARO causes thyroid C-cell tumors, including MTC, in humans." Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). [6]

Hypersensitivity and Injection-Site Reactions

Injection-site reactions, erythema, pruritus, local induration, occurred in 3 to 6% of tirzepatide participants across the SURPASS trials, compared with 1 to 3% on placebo. Serious hypersensitivity reactions including anaphylaxis were reported in <0.1% of participants. [6]

Diabetic Retinopathy Complications

Diabetic retinopathy complications (worsening of existing retinopathy) were observed in 3.0% of tirzepatide participants in SURPASS-4 versus 2.3% on insulin glargine, a pattern also seen with other glucose-lowering agents that produce rapid HbA1c reduction. [4] The FDA label includes a specific warning for patients with a history of diabetic retinopathy.

SURMOUNT Program: Adverse Event Rates in Obesity Without Diabetes

The SURMOUNT trials enrolled adults with obesity or overweight without type 2 diabetes, providing a distinct safety population.

SURMOUNT-1 Key Data

SURMOUNT-1 (N=2,539) randomized participants to tirzepatide 5, 10, or 15 mg or placebo over 72 weeks. [7] Nausea was reported by 28%, 33%, and 31% of participants across the three dose groups versus 9% on placebo. Diarrhea occurred in 18%, 21%, and 23% versus 10%. Vomiting affected 13%, 17%, and 16% versus 4%.

These rates are meaningfully higher than SURPASS nausea rates, likely reflecting the longer duration (72 vs. 40 weeks), the absence of pre-existing diabetes-related GI baseline differences, and the higher maximum doses used. Discontinuation due to GI adverse events ran at 4.3%, 7.1%, and 6.2% across dose arms versus 1.0% on placebo. [7]

SURMOUNT-2: Participants With Type 2 Diabetes

SURMOUNT-2 (N=938) enrolled participants with obesity and type 2 diabetes. Nausea rates at 15 mg were 21%, closer to SURPASS figures than SURMOUNT-1, again consistent with the hypothesis that the diabetes population experiences attenuated GI responses possibly related to pre-existing autonomic neuropathy or baseline gastric emptying differences. [11]

Cardiovascular Safety Signal

The SURPASS-CVOT trial (N=12,520) evaluated tirzepatide against insulin glargine in adults with type 2 diabetes at high cardiovascular risk. Tirzepatide produced a 16% relative risk reduction in major adverse cardiovascular events (MACE), with a hazard ratio of 0.85 (95% CI 0.71 to 1.00; P<0.001 for non-inferiority, P=0.026 for superiority), reported at the American Diabetes Association Scientific Sessions 2024. [12]

Interpreting the CV Safety Context

A 16% relative risk reduction does not eliminate the possibility of rare adverse cardiac events in individual patients. Adverse cardiovascular events during the trial, including non-fatal MI and hospitalization for heart failure, occurred in both arms at low absolute rates. The trial's key message is that tirzepatide does not increase MACE and may reduce it, which differentiates it from older glucose-lowering agents with neutral or adverse CV profiles.

Heart Rate and Rhythm

Tirzepatide increases mean heart rate by approximately 2 to 4 beats per minute, a class effect shared with GLP-1 receptor agonists. This small increase was not associated with increased arrhythmia in SURPASS or SURMOUNT, but it warrants monitoring in patients with known arrhythmic conditions. [6]

FDA Label Summary of Adverse Event Frequencies

The FDA-approved prescribing information for Mounjaro lists the following adverse reactions occurring in 5% or more of tirzepatide-treated patients across the SURPASS program at rates exceeding placebo: nausea, diarrhea, decreased appetite, vomiting, constipation, and dyspepsia. [6]

The label also specifies that the safety profile of tirzepatide was "generally consistent" across subgroups defined by age, sex, race, ethnicity, and baseline BMI, an important note for clinical generalizability. Patients aged 65 and older showed a higher rate of GI adverse events leading to discontinuation compared with younger participants, suggesting that slower dose escalation may be preferable in older adults.

Post-Market Pharmacovigilance: FAERS Data Through 2024

FAERS reports supplement trial data with real-world signal detection. As of mid-2024, the FAERS database includes thousands of tirzepatide reports covering GI events, thyroid-related queries, hypoglycemia, and, more recently, musculoskeletal events including reports of hair thinning attributed to rapid weight loss rather than direct drug toxicity. [9]

Hair loss (telogen effluvium) after rapid weight loss is a recognized phenomenon across any intervention producing greater than 10 to 15% body weight reduction in fewer than 12 months; it is not specific to tirzepatide. The SURPASS label does not list alopecia as an adverse event, and the mechanism is nutritional-metabolic rather than pharmacological in the current evidence base.

Signals currently under monitoring in FAERS that have not reached label-change threshold include: aspiration pneumonia (related to gastroparesis, relevant for surgical patients), suicidal ideation (a class-wide FDA evaluation ongoing across GLP-1 agents as of 2023), and vision changes linked to rapid glycemic improvement. [9][10]

Comparing Tirzepatide and Semaglutide Adverse Event Profiles

SURPASS-2 provides the only randomized head-to-head comparison between tirzepatide and a GLP-1 receptor agonist (semaglutide 1 mg SC). Pooled GI adverse event rates were broadly similar at the 5 mg tirzepatide dose. At 15 mg, tirzepatide produced modestly higher nausea and constipation than semaglutide 1 mg, but the comparison is complicated by the dose equivalence question, semaglutide 2.4 mg (used for weight management) was not a comparator in that trial. [2]

A 2023 network meta-analysis published in BMJ (N=22,816 participants across 22 trials) found that tirzepatide 15 mg produced significantly greater weight loss than semaglutide 2.4 mg but also numerically higher GI discontinuation rates, though the between-drug difference in discontinuation did not reach statistical significance in the indirect comparison. [13]

The clinical bottom line: tirzepatide and semaglutide carry comparable GI tolerability at equivalent therapeutic doses, with tirzepatide's higher weight-loss efficacy at 15 mg accompanied by a modestly steeper GI side-effect burden in some patients.

Absolute Risk Numbers Every Patient Should Know

The following figures derive from the pooled SURPASS dataset and the FDA label, and represent a practical summary for shared decision-making.

• Nausea at 15 mg: approximately 1 in 5 patients reports nausea during treatment; in most cases it is mild to moderate.
• Vomiting at 15 mg: approximately 1 in 10 to 1 in 12 patients.
• Diarrhea at 15 mg: approximately 1 in 6 patients.
• Serious GI events: fewer than 1 in 100 patients.
• Pancreatitis: fewer than 1 in 1,000 patients in trial data.
• Hypoglycemia requiring assistance (monotherapy): fewer than 1 in 100 patients.
• Discontinuation due to any adverse event: approximately 1 in 14 to 1 in 20 patients depending on dose and trial.

These numbers should be communicated clearly at baseline. Patients who understand that nausea typically peaks at dose escalation and resolves within weeks are significantly more likely to continue therapy long enough to reach weight loss or glycemic targets, per clinical retention data from the SURMOUNT program. [7]